Form 4: Unicycive Therapeutics CEO Receives Stock Grant
Insider Transaction Filing
Unicycive Therapeutics CEO Shalabh K. Gupta was granted 762,200 restricted stock units, vesting over three years.
Summary
- Shalabh K. Gupta, CEO and Director of Unicycive Therapeutics, Inc., received a grant of 762,200 restricted stock units (RSUs) on May 14, 2026.
- These RSUs are payable solely in common stock of the issuer.
- The shares subject to the RSU award vest in three equal installments on the anniversary of the grant date over a three-year period.
- Vesting is contingent upon Mr. Gupta's continued service with the company.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices rather than significant company performance news.
Positives
- Grant of a significant number of RSUs to the CEO indicates a long-term incentive and alignment with company performance.
- The vesting schedule over three years encourages retention and sustained commitment from leadership.
Risks
- Vesting is subject to continued service, meaning any departure before full vesting would result in forfeiture of unvested RSUs.
- The value of the RSUs is directly tied to the performance and stock price of Unicycive Therapeutics, Inc.
Future Outlook
The RSUs vest over three years, with 1/3 vesting annually, contingent on continued service. This suggests a forward-looking incentive structure for the CEO.
Industry Context
StockSavvy.ai notes that grants of restricted stock units to senior executives are a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term growth and align executive interests with shareholder value.
Stakeholder Impact
- Shareholders: The RSU grant aligns CEO incentives with long-term company performance, potentially benefiting shareholders if the company succeeds.
- Employees: May signal a stable leadership structure, though direct impact is limited.
- Management: Reinforces the CEO's commitment to the company through a performance-based incentive.
Next Steps
- Vesting of RSUs over the next three years, subject to continued service.
- Monitoring of Unicycive Therapeutics' stock performance and company developments.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of earliest transaction; Grant date of Restricted Stock Units. |
| 05/21/2026 | Date of signature on the Form 4 filing. |
Keywords
Unicycive Therapeutics, Shalabh K. Gupta, Restricted Stock Units, RSU Grant, CEO Compensation, Insider Transaction, Form 4, SEC Filing, Equity Award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.